Citius Pharmaceuticals, Inc. 8-K

What Happened
Citius Pharmaceuticals, Inc. (CTXR) filed an 8-K on March 10, 2026 reporting that its majority-owned subsidiary, Citius Oncology, Inc. (Nasdaq: CTOR), issued a press release announcing positive topline results from a completed investigator-initiated Phase 1 clinical trial. The University of Pittsburgh investigators conducted the study, which evaluated LYMPHIR™ (denileukin diftitox-cxdl) in combination with the PD‑1 inhibitor pembrolizumab (KEYTRUDA®) in patients with recurrent or refractory gynecologic cancers, including ovarian and endometrial malignancies. The press release is attached to the filing as Exhibit 99.1.

Key Details

• Filing date: March 10, 2026; subsidiary: Citius Oncology, Inc. (Nasdaq: CTOR).
• Study type: Investigator-initiated, completed Phase 1 clinical trial (University of Pittsburgh investigators).
• Treatment evaluated: LYMPHIR™ (denileukin diftitox-cxdl) combined with pembrolizumab (KEYTRUDA®).
• Indications studied: Recurrent or refractory gynecologic cancers, including ovarian and endometrial cancers; press release attached as Exhibit 99.1.

Why It Matters
Positive topline Phase 1 results are an early clinical milestone for LYMPHIR’s development when used with a PD‑1 inhibitor, and the announcement may affect investor interest in Citius’s oncology pipeline. The 8-K does not provide detailed data, financial impact, or next-step regulatory actions in the filing itself; investors should look for the full data release or subsequent company updates for specifics on efficacy, safety, and development plans.